SALAZOPYRIN TAB 500MG 500 MG
SULFASALAZINE : 500 MG · DIN 02064480 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is SALAZOPYRIN TAB 500MG?
SALAZOPYRIN TAB 500MG 500 MG contains SULFASALAZINE : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02064480, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Jan-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SALAZOPYRIN TAB 500MG used for?
SALAZOPYRIN (sulfasalazine) is indicated as an adjunctive therapy in the treatment of severe ulcerative colitis, proctitis or distal ulcerative colitis and Crohn's disease. It is especially useful for chronic administration. SALAZOPYRIN EN-tabs (sulfasalazine delayed-release tablets) are indicated for the treatment of active rheumatoid arthritis, when treatment with an adequate conventional first line therapy has failed.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is SALAZOPYRIN TAB 500MG called?
The same molecule, SULFASALAZINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Salazopyrin | Latin | Australia, Morocco |
| Pyralin EN | Latin | Australia |
| Salazopyrin-EN | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02064480 |
|---|---|
| Brand name | SALAZOPYRIN TAB 500MG |
| Generic / active ingredient | SULFASALAZINE : 500 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A07EC01 SULFASALAZINE |
| AHFS class | 08:12.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Jan-2006 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02064480 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2064480 |
| Brand name | SALAZOPYRIN TAB 500MG |
| Active ingredient / INN | SULFASALAZINE : 500 MG |
| ATC code | A07EC01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A07 |
| AHFS class | 08:12.20 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PFIZER CANADA ULC |
How is it stored and handled?
null
How is it supplied?
null
Which pack is which?
| Strength on the label | 500 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | null |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code A07EC01 SULFASALAZINE. 5 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP SULFASALAZINE | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02544652 |
| PMS-SULFASALAZINE 500MG/TAB USP | 500 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 00598461 |
| PMS-SULFASALAZINE-E.C. TAB 500MG | 500 MG | TABLET (ENTERIC-COATED) | PHARMASCIENCE INC | MARKETED | DIN 00598488 |
| SALAZOPYRIN EN-TABS 500 MG | 500 MG | TABLET (ENTERIC-COATED) | PFIZER CANADA ULC | MARKETED | DIN 02064472 |
| APO SULFASALAZINE TAB 500MG | 500 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00410640 |
| ORB-SULFASALAZINE EC | 500 MG | TABLET (ENTERIC-COATED) | ORBUS PHARMA INC | CANCELLED (UNRETURNED ANNUAL) | DIN 02246803 |
| RATIO-SULFASALAZINE EN | 500 MG | TABLET (ENTERIC-COATED) | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 00685925 |
| RATIO-SULFASALAZINE TAB 500MG | 500 MG | TABLET | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 00685933 |
| S.A.S. ENTERIC 500MG | 500 MG | TABLET (ENTERIC-COATED) | ICN CANADA LTD. | CANCELLED POST MARKET | DIN 00445126 |
| SALAZOPYRIN ENEMA 3.0GM/100ML | 3 G / 100 ML | SUSPENSION | KABI PHARMACIA CANADA INC. | CANCELLED POST MARKET | DIN 02004682 |
Who else supplies SULFASALAZINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SULFASALAZINE appears in 28 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does SULFASALAZINE cost around the world?
SULFASALAZINE is listed on 7 national price registers Nexara tracks, across 25 pack listings published on 6 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 1 | 12 | 03 Sep 2026 |
| Australia | ex-manufacturer | 3 | 6 | 08 Sep 2026 |
| United Kingdom | hospital | 3 | 3 | 31 Aug 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Morocco | PPV (public price) | 1 | 1 | 05 Sep 2026 |
| Saudi Arabia | public | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.